Open an account

XORTX Therapeutics

XRTX · TSX

$0.9201−$0.0487 (−5.03%)TodayMarket closed ·
Prev close $0.9688

About XRTX

XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. The company has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. The company is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.

Employees
3
Headquarters
Calgary, Alberta
Listed
Sep 30, 2015
Sector
Health Care
Industry
Pharmaceuticals
Website
xortx.com

XRTX key statistics

Market cap
2.37M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.58M
Volume
20.23K
Open price
$0.9201
High today
$0.95
Low today
$0.915
52 Week high
$3.89
52 Week low
$0.3456

XORTX Therapeutics (XRTX) at a glance

As of Oct 23, 2026, XORTX Therapeutics (XRTX) shares are priced at $0.9201, giving the company a market cap of 2.37M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.915 and $0.95. The current price is 0.6% above the day's low and 3.1% below its high.

Volume so far is 20.23K shares, below the average of 1.58M shares a day.

Over the past year XORTX Therapeutics has ranged from $0.3456 to $3.89, and now sits 16% of the way up that range.

XORTX Therapeutics met or beat analyst EPS estimates in 4 of the last 6 quarters. In Q1 FY24 it reported -$1.24 per share against an estimate of -$0.2626.

XRTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 6 quarters, by 45.4% on average.

  1. Q1 FY22: reported -$11.70 per share against an estimate of -$8.72
  2. Q2 FY22: reported -$5.40 per share against an estimate of -$10.83
  3. Q4 FY22: reported -$9.00 per share against an estimate of -$12.27
  4. Q1 FY23: reported -$4.95 per share against an estimate of -$10.45
  5. Q2 FY23: reported -$5.45 per share against an estimate of -$11.36
  6. Q1 FY24: reported -$1.24 per share against an estimate of -$0.2626

XRTX news

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Mohd Haider

    XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why

  • Mohd Haider

    XORTX Therapeutics (XRTX) Stock Climbs 16% After Hours: Here's What You Need to Know

  • Press releaseGlobe Newswire

    XORTX Re-Engages Investor Relations Program

  • XORTX Therapeutics Terminates And Postpones Investor Relations And Marketing Agreement With IR Agency

  • Press releaseGlobe Newswire

    XORTX Announces Termination and Postponement of Investor Relations Program

  • Press releaseGlobe Newswire

    XORTX Announces Director Resignation

  • Press releaseGlobe Newswire

    XORTX Appoints New Director

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.